During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and radiation. This approach utilizes the host’s immune response, which is triggered by cancer cells expressing tumor-associated antigens or neoantigens. The responsive immune cytotoxic CD8+ T cells specifically target and kill tumor cells, leading to tumor regression and prolongation of survival in some cancers; however, some cancers may exhibit resistance due to the inactivation of anti-tumor CD8+ T cells. One mechanism by which the anti-tumor CD8+ T cells become dysfunctional is through the activation of the inhibitory receptor programmed death-1 (PD-1) by the corresponding tumor cells (or other cells in the tumor microenvironment (TME)) that express the programmed death ligand-1 (PD-L1). Hence, blocking the PD-1/PD-L1 interaction via specific monoclonal antibodies (mAbs) restores the CD8+ T cells’ functions, leading to tumor regression. Accordingly, the Food and Drug Administration (FDA) has approved several checkpoint antibodies which act as immune checkpoint inhibitors. Their clinical use in various resistant cancers, such as metastatic melanoma and non-small-cell lung cancer (NSCLC), has shown significant clinical responses. We have investigated an alternative approach to prevent the expression of PD-L1 on tumor cells, through targeting the oncogenic transcription factor Yin Yang 1 (YY1), a known factor overexpressed in many cancers. We report the regulation of PD-L1 by YY1 at the transcriptional, post-transcriptional, and post-translational levels, resulting in the restoration of CD8+ T cells’ anti-tumor functions. We have performed bioinformatic analyses to further explore the relationship between both YY1 and PD-L1 in cancer and to corroborate these findings. In addition to its regulation of PD-L1, YY1 has several other anti-cancer activities, such as the regulation of proliferation and cell viability, invasion, epithelial–mesenchymal transition (EMT), metastasis, and chemo-immuno-resistance. Thus, targeting YY1 will have a multitude of anti-tumor activities resulting in a significant obliteration of cancer oncogenic activities. Various strategies are proposed to selectively target YY1 in human cancers and present a promising novel therapeutic approach for treating unresponsive cancer phenotypes. These findings underscore the distinct regulatory roles of YY1 and PD-L1 (CD274) in cancer progression and therapeutic response.
Ballast water (BW) is a major pathway for the spread of invasive microorganisms and pathogens, posing significant ecological and public health risks. The International Maritime Organization (IMO) has established strict discharge standards, yet routine monitoring remains limited, and no reliable onboard test is currently available to assist crews in verifying BW quality before discharge. This study presents the development of a rapid, portable method for onboard microbiological assessment of BW, based on potentiometric detection and biosensors engineered with the Bioelectric Recognition Assay (BERA). Two complementary approaches were evaluated: (i) direct potentiometric measurements of contaminated and non-contaminated samples, which confirmed the feasibility of detecting microbial presence but were restricted by high detection limits, and (ii) development of biosensors specifically engineered for Escherichia coli and Enterococcus spp. to improve specificity and lower the limit of detection (LOD). Results demonstrated successful detection of both microorganisms, with performance characteristics of 83.3% sensitivity and 81.9% accuracy for Enterococcus spp. (LOD: 102 CFU 100 mL−1), and 89.8% sensitivity and 85.1% accuracy for Escherichia coli (LOD: 250 CFU 100 mL−1). These findings underscore the potential of biosensor-based systems as practical, crew-operated tools for early warning and real-time monitoring of ballast water quality, supporting compliance with IMO standards and contributing to safer, more sustainable maritime operations.